Anistreplase

Jump to: navigation, search
Anistreplase
Clinical data
ATC code
Identifiers
CAS Number
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC2569H3928N746O781S40
Molar mass59042.3 g/mol

WikiDoc Resources for Anistreplase

Articles

Most recent articles on Anistreplase

Most cited articles on Anistreplase

Review articles on Anistreplase

Articles on Anistreplase in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Anistreplase

Images of Anistreplase

Photos of Anistreplase

Podcasts & MP3s on Anistreplase

Videos on Anistreplase

Evidence Based Medicine

Cochrane Collaboration on Anistreplase

Bandolier on Anistreplase

TRIP on Anistreplase

Clinical Trials

Ongoing Trials on Anistreplase at Clinical Trials.gov

Trial results on Anistreplase

Clinical Trials on Anistreplase at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Anistreplase

NICE Guidance on Anistreplase

NHS PRODIGY Guidance

FDA on Anistreplase

CDC on Anistreplase

Books

Books on Anistreplase

News

Anistreplase in the news

Be alerted to news on Anistreplase

News trends on Anistreplase

Commentary

Blogs on Anistreplase

Definitions

Definitions of Anistreplase

Patient Resources / Community

Patient resources on Anistreplase

Discussion groups on Anistreplase

Patient Handouts on Anistreplase

Directions to Hospitals Treating Anistreplase

Risk calculators and risk factors for Anistreplase

Healthcare Provider Resources

Symptoms of Anistreplase

Causes & Risk Factors for Anistreplase

Diagnostic studies for Anistreplase

Treatment of Anistreplase

Continuing Medical Education (CME)

CME Programs on Anistreplase

International

Anistreplase en Espanol

Anistreplase en Francais

Business

Anistreplase in the Marketplace

Patents on Anistreplase

Experimental / Informatics

List of terms related to Anistreplase

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Anistreplase is a thrombolytic drug.[1][2][3]

Anistreplase has been developed by Beecham as Eminase. It is also known as anisoylated plasminogen streptokinase activator complex (APSAC)

Mechanism

It is a complex of purified human plasminogen and bacterial streptokinase that has been acylated to protect the enzyme's active site. When the drug is administered, the acyl group gets hydrolyzed, thereby freeing the activator complex. It converts plasminogen to plasmin, which in turn degrades fibrin (blood clots) to fibrin split products.

References

  1. Rawles J (January 1996). "Magnitude of benefit from earlier thrombolytic treatment in acute myocardial infarction: new evidence from Grampian region early anistreplase trial (GREAT)". BMJ. 312 (7025): 212–5. doi:10.1136/bmj.312.7025.212. PMC 2350007. PMID 8563585.
  2. Hannaford P, Vincent R, Ferry S, Hirsch S, Kay C (April 1995). "Assessment of the practicality and safety of thrombolysis with anistreplase given by general practitioners". Br J Gen Pract. 45 (393): 175–9. PMC 1239197. PMID 7612317.
  3. Rawles J, Light J (October 1993). "Loss of quality adjusted days as a trial endpoint: effect of early thrombolytic treatment in suspected myocardial infarction. Grampion Region Early Anistreplase Trial (GREAT)". J Epidemiol Community Health. 47 (5): 377–381. doi:10.1136/jech.47.5.377. PMC 1059832. PMID 8289038.

Linked-in.jpg